Trial Profile

An Open Label, Dose Range, Proof-of-Concept Study to Assess the Safety and Efficacy of HM15421/GC1134A in Patients With Fabry Disease

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HM 15421 (Primary)
Indications Fabry's disease
Focus Adverse reactions; First in man; Proof of concept
Sponsors GC Biopharma

Most Recent Events

05 Mar 2025 Status changed from planning to not yet recruiting.
11 Sep 2024 New trial record
03 Sep 2024 According to a GC Biopharma media release, company nnounced that its collaborative project for Fabry treatment 'LA-GLA' (HM15421/GC1134A) with GC Biopharma has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com